Article ID Journal Published Year Pages File Type
10484777 Value in Health 2015 8 Pages PDF
Abstract
In the overall trial population, LDX was associated with a lower rate of treatment failure compared with OROS-MPH in patients with ADHD. A more pronounced benefit of LDX over OROS-MPH was observed among subpopulations with a higher predicted risk of failing OROS-MPH. The present study showed the feasibility of individualizing treatment selection. Future research is needed to prospectively verify these results.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, , , , , , , ,